Literature DB >> 14678044

Testosterone concentrations and sirolimus in male renal transplant patients.

Lutz Fritsche1, Klemens Budde, Duska Dragun, Gunilla Einecke, Fritz Diekmann, Hans-Hellmut Neumayer.   

Abstract

Sirolimus damages the testes in animals; however, human data are sparse. We conducted a case-control study to obtain further insight into this issue and compared testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin concentrations in matched renal transplant patients who did or did not receive sirolimus. We found that testosterone values were lower (11.2 +/- 6.3 nmol/L vs. 15.5 +/- 7.7 nmol/L, p < 0.05), in 28 sirolimus-treated patients, compared to 28 non-sirolimus-treated controls. Furthermore, these patients more commonly had testosterone concentrations that were below our reference value for normal men. In contrast, FSH and LH concentrations were higher while prolactin levels were not different. These data are consistent with sirolimus-related testosterone suppression and suggest a need for further studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678044     DOI: 10.1046/j.1600-6135.2003.00279.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  23 in total

Review 1.  The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.

Authors:  Bradley C Holland; Zubin Shetty; Shaheen Alanee
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

Review 2.  [Modern immunosuppression following renal transplantation. Standard or tailor made?].

Authors:  K Budde; M Giessing; L Liefeldt; H-H Neumayer; P Glander
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

3.  Sirolimus rescue of renal failure in children after combined liver-kidney transplantation.

Authors:  Udo Vester; Birgitta Kranz; Silvio Nadalin; Andreas Paul; Jan Becker; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

Review 4.  Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.

Authors:  S Brakemeier; F Bachmann; K Budde
Journal:  Pediatr Nephrol       Date:  2016-09-01       Impact factor: 3.714

5.  Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation.

Authors:  Birgitta Kranz; Anne-Margret Wingen; Udo Vester; Jens König; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2013-04-13       Impact factor: 3.714

6.  Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus.

Authors:  Yousef Boobes; Bassam Bernieh; Hussein Saadi; M Raafat Al Hakim; Samra Abouchacra
Journal:  Int Urol Nephrol       Date:  2009-09-23       Impact factor: 2.370

7.  The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.

Authors:  K Chamie; P M Ghosh; T M Koppie; V Romero; C Troppmann; R W deVere White
Journal:  Am J Transplant       Date:  2008-10-06       Impact factor: 8.086

8.  Measurements of serum pituitary-gonadal hormones and investigation of sexual and reproductive functions in kidney transplant recipients.

Authors:  Guang-Chun Wang; Jun-Hua Zheng; Long-Gen Xu; Zhi-Lian Min; You-Hua Zhu; Jun Qi; Qiang-Lin Duan
Journal:  Int J Nephrol       Date:  2010-07-27

Review 9.  Treating erectile dysfunction in renal transplant recipients.

Authors:  John M Barry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  HCG-mediated activation of mTORC1 signaling plays a crucial role in steroidogenesis in human granulosa lutein cells.

Authors:  Molly B Moravek; Min Shang; Bindu Menon; Kmj Menon
Journal:  Endocrine       Date:  2016-08-08       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.